.png)
At PromiCell, our mission is to transform cancer care by advancing groundbreaking CAR T and TCR therapies. Through innovation, collaboration with world-class institutions, and a relentless focus on patients, we aim to deliver life-changing solutions that address critical gaps in oncology and provide new hope for those fighting cancer.
PromiCell’s advanced CAR T and TCR T platforms are designed to overcome the toughest challenges in oncology. By integrating cutting-edge genetic engineering, our therapies address tumor resistance, improve anti-tumor responses, and enhance durability. With innovations like IL-18 cytokine armoring and fully human constructs, our solutions offer unmatched precision and safety, targeting both antigen-positive and antigen-negative tumors while providing lasting outcomes for patients.
PromiCell’s therapies are backed by robust preclinical data that demonstrate their transformative potential. Our CAR T and TCR therapies have achieved robust tumor clearance in prostate cancer and Ewing Sarcoma models. With FDA-allowed Phase 1 trials already underway, our pipeline is supported by extensive safety and efficacy studies, laying a strong foundation for clinical success and delivering hope to patients facing difficulties to treat cancers.
PromiCell’s exclusive collaborations with Fred Hutchinson and MSK Cancer Center provide access to world-class clinical expertise and cell manufacturing. These partnerships enable us to accelerate breakthroughs in targeting critical unmet needs, including prostate cancer, acute myeloid leukemia (AML), and Ewing Sarcoma. Together, we are driving innovation to bring next-generation cellular therapies to patients who need them most.
To build a fully integrated cell therapy company with a focus on delivering transformative solutions for solid and hematologic cancers. With multiple clinical programs and scalable platforms, PromiCell is poised to become a leader in delivering the next wave of novel cancer treatments.
PromiCell integrates automated, GMP-compliant manufacturing platforms, reducing costs and ensuring the consistent production of high-quality cell therapies.
Collaborations with Fred Hutchinson (FH) and Memorial Sloan Kettering (MSK) Cancer Center provide access to cutting-edge research, world-class infrastructure, and unparalleled clinical expertise. These partnerships de-risk novel proprietary technologies, accelerating clinical development and the path to market.
STEAP1 CAR T: Targeting metastatic castration-resistant prostate cancer, now in Phase 1 trials with preclinical data showing complete tumor response within 5 weeks.
HA-1 TCR T: Focused on leukemia relapse following bone marrow transplants, with first-in-human trials showing a sign of chemical response.
CD33 CAR T: Targeting at acute myeloid leukemia, demonstrating superior potency over current best-in-class CAR T therapies in preclinical models.
PromiCell combines science, strategy, and operational excellence to address unmet needs in cancer care. Our innovative approach ensures multiple opportunities for success:
Market Potential: Addressing cancers with large patient populations and significant demand for innovative therapies.
Risk Mitigation: Leveraging proven technologies and strong clinical partnerships to de-risk our programs.
Path to Commercialization: Advancing from Phase 1 to Phase 2 clinical trials while exploring global expansion opportunities.